Developing broad-spectrum vaccines and optimal vaccination strategies is crucial to
controlling the COVID-19 pandemic. Here, we generated a chimpanzee adenoviral vector …

Adenovirus vector vaccines have been widely and successfully deployed in response to
coronavirus disease 2019 (COVID-19). However, despite inducing potent T cell immunity …

The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) caused an ongoing
unprecedented global public health crises of coronavirus disease in 2019 (CoVID-19). The …

Remarkable progress has been made in developing intramuscular vaccines against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, they are limited with …

Severe respiratory viral infections, such as influenza, metapneumovirus (HMPV), respiratory
syncytial virus (RSV), rhinovirus (RV), and coronaviruses, including severe acute respiratory …

Transmission-blocking strategies that slow the spread of SARS-CoV-2 and protect against
COVID-19 are needed. We have developed a shelf-stable, orally-delivered Ad5-vectored …

Covid‐19 vaccines have within the first year prevented about 14 million deaths but did not
induce a strong mucosal immune response. Data from US, UK, Singapore and Israel …

The first two mRNA vaccines against infection by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that were approved by regulators require a cold chain and …

As of September 2021, twenty-one anti-COVID-19 vaccines have been approved in the
world. Their utilization will expedite an end to the current pandemic. Besides the usual …

Current parenteral coronavirus disease 2019 (Covid-19) vaccines inadequately protect
against infection of the upper respiratory tract. Additionally, antibodies generated by wild …